What’s new in treatment of pancreatic cancer: a patent review (2010–2017)

References

• Cancer Facts and Figures. American Cancer Society. 2017 [cited 2017 May 26]. Available from: https://old.cancer.org/acs/groups/content/@editorial/documents/document/acspc-048738.pdf
   Google Scholar
• Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–291.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313–323.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–361.
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri N, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663–666.
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 2010;10(4):529–540.
   PubMed Web of Science ®Google Scholar
• Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–3510.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist. 2008;13:562–576.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Apps MG, Choi EH, Wheate NJ. The state-of-play and future of platinum drugs. Endocr Relat Cancer. 2015;22(4):R219–33.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(11):4548–4554.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Pancreatic Cancer Treatment (PDQ®). PDQ cancer information summaries. Bethesda (MD): National Cancer Institute (US); 2017 [cited 2017 May 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65957/#CDR0000062951__128
   Google Scholar
• Japan Adjuvant Study Group of Pancreatic Cancer. Neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer. NCT02459652. 2015 [cited 2017 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02459652?term=JASPAC&rank=1
   Google Scholar
• Collins MA, Bednar F, Zhang Y, et al. Oncogenic K-ras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122:639–653.
   PubMed Web of Science ®Google Scholar
• Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.
   PubMed Web of Science ®Google Scholar
• Boschman CR, Stryker S, Reddy JK, et al. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol. 1994;145:1291–1295.
   PubMed Web of Science ®Google Scholar
• Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012;13:802–810.
   PubMed Web of Science ®Google Scholar
• Nowak NJ, Gaile D, Conroy JM, et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet. 2005;161:36–50.
   PubMed Web of Science ®Google Scholar
• Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al. Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest. 2001;81:1439–1451.
   PubMed Web of Science ®Google Scholar
• Valsecchi ME, McDonald M, Brody JR, et al. Epidermal growth factor receptor and insulin like growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118:3484–3493.
   PubMed Web of Science ®Google Scholar
• Gavert N, Ben-Ze’ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med. 2008;14:199–209.
   PubMed Web of Science ®Google Scholar
• Ho MY, Tang SJ, Chuang MJ, et al. TNF-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3beta-dependent mechanism. Mol Cancer Res. 2012;10:1109–1119.
   PubMed Web of Science ®Google Scholar
• Mazur PK, Einwächter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2010;107(30):13438–13443.
   PubMed Web of Science ®Google Scholar
• Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13:4769–4776.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27(13):2231–2237.
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605–3610.
   PubMed Web of Science ®Google Scholar
• Rieder S, Michalski CW, Friess H, et al. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anticancer Agents Med Chem. 2011;11:427–433.
   PubMed Web of Science ®Google Scholar
• Wu M. Traditional Chinese patent medicines for cancer treatment in China: a nationwide medical insurance data analysis. Oncotarget. 2015;6(35):38283–38295.
   PubMed Web of Science ®Google Scholar
• Changshu City Yushan Green Tea CO LTD. Chinese medicine preparation for treating pancreas cancer. CN102526542. 2012.
   Google Scholar
• Wei S. Traditional Chinese medicine preparation for treating pancreas cancer and preparation method thereof. CN103386024. 2013.
   Google Scholar
• Pharmaceutical Res & Dev Corp of Jingpenghui. Use of albiflorin in preparation of pancreas cancer resistant medicines. CN104706647. 2015.
   Google Scholar
• Erytech Pharma. Medicament for the treatment of cancer of the pancreas. CN101932335. 2010.
   Google Scholar
• Erytech Pharma. Administration of GRASPA (suspension of erythrocytes encapsulating L-asparaginase) in patients with pancreatic cancer. NCT01523808. 2012–2013 [cited 2017 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01523808?term=asparaginase+pancreatic+cancer&rank=1
   Google Scholar
• ERYtech Pharma. Efficacy and safety of L-asparaginase encapsulated in RBC combined with gemcitabine or FOLFOX in 2nd line for progressive metastatic pancreatic carcinoma. NCT02195180. 2014–2016 [cited 2017 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02195180?term =asparaginase+pancreatic+cancer&rank=2
   Google Scholar
• Abraxis Bioscience Llc. Methods of treatment of pancreatic cancer. US2017049711. 2017.
   Google Scholar
• Biocompatibles UK LTD. Therapy of pancreatic cancer. JP2014208661. 2014.
   Google Scholar
• Merrimack Pharmaceuticals Inc. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan. WO2013188586. 2013.
   Google Scholar
• Merrimack Pharmaceuticals. Study of MM-398 with or without 5-FU/LV, versus 5-FU/LV in patients with metastatic pancreatic cancer (NAPOLI-1). NCT01494506. 2011–2016 [cited 2017 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01494506?term=MM-398&rank=3&sect=X70156
   Google Scholar
• Irinotecan liposome injection. Approved drugs. US Food & Drugs Administration. 2015 [cited 2017 Mar 9]. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm468728.htm
   Google Scholar
• Merrimack Pharmaceuticals Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin. WO2017034957. 2017.
   Google Scholar
• Genvec Inc. Therapeutic regimen for treating cancer. ES2340038. 2010.
   Google Scholar
• Baher AG, Andres ML, Folz-Holbeck J, et al. A model using radiation and plasmid-mediated tumor necrosis factor-alpha gene therapy for treatment of glioblastomas. Anticancer Res. 1999;19(4B):2917–2924.
   PubMed Web of Science ®Google Scholar
• Deutsches Krebsforsch, Univ Ruprecht Karls Heidelberg. Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer CA2845637. 2013.
   Google Scholar
• Angelov AL, Abrahamian M, Grekova SP, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus HPV. Clin Cancer Res. 2009;15:511–519.
   PubMed Web of Science ®Google Scholar
• Oryx GmbH & Co. KG. Parvovirus H-1 (ParvOryx) in patients with metastatic inoperable pancreatic cancer (ParvOryx02). NCT02653313. 2015–2016. [cited 2017 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02653313?term=parvovirus+pancreatic+cancer&rank=1
   Google Scholar
• Univ Oita. A combination therapy of selective infusion therapy of anticancer drug to pancreas artery and systemic chemotherapy for pancreas cancer, and pancreas cancer therapeutic agent used for the same. JP2011079788. 2011.
   Google Scholar
• Univ Leland Stanford Junior. Systems and methods for treating pancreatic cancer. US20150018725. 2015.
   Google Scholar
• Renovorx INC. Methods for delivery of therapeutic materials to treat pancreatic cancer. US2017056629. 2017.
   Google Scholar
• Kotteas E, Saif MW, Syrigos K. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol. 2016;142(8):1795–1805.
   PubMed Web of Science ®Google Scholar
• Oncotherapy Science Inc. Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent. MX2010002178. 2010.
   Google Scholar
• Vaximm A DNA vaccine for use in pancreatic cancer patients. WO2014005683. 2014.
   Google Scholar
• Innocimab Pte Ltd, Oncoscience Ag. Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (EGFR). WO2017017133. 2017.
   Google Scholar
• Baylor Res Inst. Dendritic cell (DC)-vaccine therapy for pancreatic cancer. AR087380. 2014.
   Google Scholar
• Neogenix Oncology Inc. Monoclonal antibody therapy for pancreas cancer. EP2295064. 2011.
   Google Scholar
• Biorealites, Inst Nat Sante Rech Med, Centre Nat Rech Scient. Methods for treating pancreatic cancer. CA2786479. 2011.
   Google Scholar
• Chau I, Cunningham D, Russell C, et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006;94(8):1107–1115.
   PubMed Web of Science ®Google Scholar
• Toray Industries, Minamida Yoshitaka, Okano Fumiyoshi, Saito Takanori. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. WO2013018886. 2013.
   Google Scholar
• Oncomed Pharm Inc. Methods of treating pancreatic cancer. WO2014151606; 2014.
   Google Scholar
• Univ Aix Marseille; Inst Nat Sante Rech Med. Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics. JP2015063524. 2015.
   Google Scholar
• Josef M, Bradu Stefan M, Raquib H, et al. Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods. US20160083475. 2016.
   Google Scholar
• Cureandsure Biotechology CO Ltd. Compound formed by pancreas cancer related peptide and heat shock protein and applications thereof. CN104211796. 2014.
   Google Scholar
• Torres MP, Chakraborty S, Souchek J, et al. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des. 2012;18(17):2472–2481.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhang X, Wang Y, et al. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity. Cancer Immunol Immunother. 2011;60(12):1763–1774.
   PubMed Web of Science ®Google Scholar
• Prec Biolog Inc. Colon and pancreas cancer peptidomimetics. US20150337023. 2015.
   Google Scholar
• Haab BB, Porter A, Yue T, et al. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Annals of Surgery. 2010;251(5):937–945.
   PubMed Web of Science ®Google Scholar
• Gen Hospital Corp Dba Massachusetts General Hospital. Antifugetactic agents for the treatment of pancreas cancer. US20160184257. 2016.
   Google Scholar
• Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–611.
   PubMed Web of Science ®Google Scholar
• Hoffmann LR. Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer. CA2804348. 2012.
   Google Scholar
• Jiangsu Sunstem Biotechnology Co Ltd. Application of SETD4 to preparation of pancreatic cancer diagnosis and/or prognosis kit and application of SETD4 blocker to preparation of medicament for treating pancreas cancer. CN104017868. 2014.
   Google Scholar
• Faria JA, Corrêa NC, de Andrade C, et al. SET domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation. J Cancer Sci Ther. 2013;5(2):58–65.
   PubMedGoogle Scholar
• Uwagawa Takashi. Antitumor agent containing 6ʹ-amidino-2ʹ-naphthyl 4-guanidinobenzoate or salt thereof. US2010015249. 2010
   Google Scholar
• Univ Fudan. Anti-pancreas cancer pharmaceutical composition, its application, pill case and package. CN103933046. 2014.
   Google Scholar
• PharmaMar SA Use of aplidine for the treatment of pancreatic cancer. US2010041594. 2010.
   Google Scholar
• Niiki Pharma Inc. Method of treating pancreatic cancer. CA2821034. 2011.
   Google Scholar
• Antonarakis ES, Emadi A. Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer Chemother Pharmacol. 2010;66(1):1–9.
   PubMed Web of Science ®Google Scholar
• Niiki Pharma Inc, Sheshbaradaran Hooshmand, Baerga Rebecca, Cobb Jenel. Method for treating pancreatic cancer. WO2011133826. 2011.
   Google Scholar
• Ardea Biosciences INC. Treatment of pancreatic cancer. MX2011009494. 2011.
   Google Scholar
• Fundación Medina Centro De Excelencia En Investigación De Medicamentos Innovadores En Andalucía. Phenol derivatives to treat cancer. WO2016174226; 2016.
   Google Scholar
• AB Science, M Alain, K Jean-Pierre. Combined treatment of pancreatic cancer with gemcitabine and masitinib. WO2011092338. 2011.
   Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting kit. PLoS One. 2009;4(9):e7258.
   PubMed Web of Science ®Google Scholar
• Murtaugh LC. The what, where, when and how of Wnt/beta-catenin signaling in pancreas development. Organogenesis. 2008;4:81–86.
   PubMedGoogle Scholar
• Piramal Healthcare Ltd, A Veena, B Arun et al. A synergistic pharmaceutical combination for the treatment of pancreatic cancer. WO2012123889. 2012.
   Google Scholar
• Pharma V, Robert PJ, Michael RP. Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors. WO2013049859. 2013.
   Google Scholar
• Karyopharm Therapeutics Inc. Polymorphs of selinexor. WO2016025904. 2016.
   Google Scholar
• Abdul Razak AR, Mau-Soerensen M, Gabrail NY. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142–4150.
   PubMed Web of Science ®Google Scholar
• Barbara Ann Karmanos Cancer Institute. Selinexor, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation in treating patients with metastatic pancreatic cancer. NCT02178436. 2014–2017 [cited 2017 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02178436?term=KPT-330+pancreatic&rank=1
   Google Scholar
• Shengyu D. Application of Sarcaboside B to medicament for treatment of pancreas cancer. CN103393668. 2013.
   Google Scholar
• Changzhou Kelixin Medical Devices Co Ltd. Application of Manzamenone O in pancreas cancer treatment medicines. CN103655552. 2014.
   Google Scholar
• Sloan Kettering Inst Cancer, Univ Rockefeller. Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines. CA2868356. 2013.
   Google Scholar
• Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–911.
   PubMed Web of Science ®Google Scholar
• Morton JP, Lewis BC. Shh signaling and pancreatic cancer: implications for therapy? Cell Cycle. 2007;6:1553–1557.
   PubMed Web of Science ®Google Scholar
• Univ Health Network. Treatment for pancreatic cancer. CA2927612. 2015.
   Google Scholar
• Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10:1311–1316.
   PubMed Web of Science ®Google Scholar
• Denis C. Mouse ‘avatars’ could aid pancreatic cancer therapy. Nature News. 2012 [published online 2012 Mar 21; cited 2017 Mar 13]. Available from: http://www.nature.com/news/mouse-avatars-could-aid-pancreatic-cancer-therapy-1.10259
   Google Scholar